Heart failure & cardiomyopathiesCohort study
An integrated Biobank in the Swedish Heart Failure Registry—clinomics, proteomics, transcriptomics and genomics
- comprehensive biobank integrated in the Swedish Heart Failure Registry (SwedeHF)
- nine hospitals with access to healthcare integrated biobanking
- optional second sampling after 6 months
Authors' conclusion
We are building a high-quality detailed biobank linked to SwedeHF, the world’s largest continuous HF registry, consisting of plasma, serum, whole blood and urine samples. The Biobank will enable studies exploring underlying disease mechanisms in HF and response to HF treatment, paving the way for precision medicine and novel drug targets. It will also generate a structure for biobanking in Registry-based Randomized Controlled Trials within the national SwedeHF registry.
Study context
- Population
- Patients with HF attending routine clinical visits at nine hospitalsfirst enrolled patients, target 5000 patients
- Participants
- 1,348 patients
- Exposure
- Biobank enrolled patients vs SwedeHF 2023 index registrations
- Biobank enrolled patientsn = 1,348
- SwedeHF 2023 index registrationsn = 8,506
Main finding
As reported in the abstract
Baseline characteristics
Females
HFrEF
HFpEF
| Outcome | Biobank enrolled patients | SwedeHF 2023 index registrations |
|---|---|---|
| Age (median) | 72 years | Not reported in the abstract |
| NT-proBNP (median, quartile 1-3) | 1240 (quartile 1-3; 470-2830) pg/mL | Not reported in the abstract |
| Age | Not reported in the abstract | 75 years |
| NT-proBNP | Not reported in the abstract | 1560 [629-3617] pg/mL |
Observational data: associations, not effects.
Original publication
An integrated Biobank in the Swedish Heart Failure Registry—clinomics, proteomics, transcriptomics and genomics. ESC Heart Fail. Published 8 April 2026. doi:10.1093/eschf/xvag092
Summarised from the published abstract; every number is checked against it